SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood. 2008; 111: 2521-2526.
  • 2
    Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008; 111: 2516-2520.
  • 3
    Lonial S, Cavenagh J. Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma. Br J Haematol. 2009; 145: 681-708.
  • 4
    San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008; 359: 906-917.
  • 5
    Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006; 24: 431-436.
  • 6
    Rajkumar SV, Rosinol L, Hussein M, et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol. 2008; 26: 2171-2177.
  • 7
    Richardson PG, Mitsiades C, Schlossman R, et al. Bortezomib in the front-line treatment of multiple myeloma. Expert Rev Anticancer Ther. 2008; 8: 1053-1072.
  • 8
    van de Velde H, Liu X, Chen G, Cakana A, Deraedt W, Bayssas M. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica. 2007; 92: 1399-1406.
  • 9
    Mitsiades N, Mitsiades CS, Poulaki V, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood. 2002; 99: 4525-4530.
  • 10
    Borrello I, Ferguson A, Huff CA, et al. Bortezomib and thalidomide treatment of newly diagnosed patients with multiple myeloma: efficacy and neurotoxicity [abstract]. Blood (ASH Annual Meeting Abstracts). 2006; 108. Abstract 3528.
  • 11
    Chen S, Jiang B, Qiu L, Yu L, Zhong Y, Gao W. Bortezomib plus thalidomide treatment of newly diagnosed patients with multiple myeloma—efficacy and neurotoxicity: results of a multicenter study [abstract]. Blood (ASH Annual Meeting Abstracts). 2007; 110. Abstract 3600.
  • 12
    Pineda-Roman M, Zangari M, van Rhee F, et al. VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma. Leukemia. 2008; 22: 1419-1427.
  • 13
    Cavo M, Tacchetti P, Patriarca F, et al. Superior complete response rate and progression-free survival after autologous transplantation with up-front Velcade-thalidomide-dexamethasone compared with thalidomide-dexamethasone in newly diagnosed multiple myeloma [abstract]. Blood (ASH Annual Meeting Abstracts). 2008; 112. Abstract 158.
  • 14
    Drach J, Odelga V, Ackermann J, et al. VTD (Velcade, thalidomide, dexamethason) represents an active induction regimen for patients with multiple myeloma. Haematologica. 2008; 93: 87-88.
  • 15
    Giralt S, Thandi R, Qazilbash M, et al. Retrospective comparison of transplant outcomes in patients with multiple myeloma according to induction therapy with thalidomide/dexamethasone (TD) with or without bortezomib (VTD) [abstract]. Blood (ASH Annual Meeting Abstracts). 2007; 110. Abstract 948.
  • 16
    Wang M, Han XH, Zhang L, et al. Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leukemia. 2008; 22: 179-185.
  • 17
    Yoon SS, Kim HJ, Lee DS, et al. Sequential VAD (vincristine, Adriamycin, dexamethasone) and VTD (bortezomib, thalidomide, dexamethasone) induction followed by high-dose therapy with autologous stem cell transplantation and maintenance treatment with bortezomib for newly diagnosed multiple myeloma. Interim results of phase II trial. Haematologica. 2008; 93: 86-87.
  • 18
    National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Multiple Myeloma (version 1.2009). Fort Washington, Pa: National Comprehensive Cancer Network; 2008.
  • 19
    Gladney SP, Lonial S, Kaufman JL. Multiple myeloma presenting with advanced renal failure: a case report and new treatment options. Clin Lymphoma Myeloma. 2008; 8: 52-54.
  • 20
    Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998; 102: 1115-1123.
  • 21
    Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006; 20: 1467-1473.
  • 22
    Cavo M, Tosi P, Zamagni E, et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol. 2007; 25: 2434-2441.
  • 23
    Harousseau J-L, Attal M, Moreau P, Garban F, Facon T, Avet-Loiseau H. The prognostic impact of complete remission (CR) plus very good partial remission (VGPR) in a double-transplantation program for newly diagnosed multiple myeloma (MM): combined results of the IFM 99 trials [abstract]. Blood (ASH Annual Meeting Abstracts). 2006; 108. Abstract 3077.
  • 24
    O'Shea D, Giles C, Terpos E, et al. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients. Bone Marrow Transplant. 2006; 37: 731-737.
  • 25
    Wang M, Delasalle K, Thomas S, Giralt S, Alexanian R. Complete remission represents the major surrogate marker of long survival in multiple myeloma [abstract]. Blood (ASH Annual Meeting Abstracts). 2006; 108. Abstract 403.
  • 26
    Hussein MA, Baz R, Srkalovic G, et al. Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma. Mayo Clin Proc. 2006; 81: 889-895.
  • 27
    Wang M, Giralt S, Handy B, et al. Complete remission and survival in multiple myeloma [abstract]. J Clin Oncol. 2008; 26. Abstract 8523.
  • 28
    Ladetto M, Pagliano G, Avonto I, et al. Consolidation with bortezomib, thalidomide and dexamethasone induces molecular remissions in autografted multiple myeloma patients [abstract]. Blood (ASH Annual Meeting Abstracts). 2007; 110. Abstract 530.
  • 29
    Bensinger W. Stem-cell transplantation for multiple myeloma in the era of novel drugs. J Clin Oncol. 2008; 26: 480-492.
  • 30
    Davies FE, Forsyth PD, Rawstron AC, et al. The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma. Br J Haematol. 2001; 112: 814-819.
  • 31
    Paiva B, Vidriales MB, Cervero J, et al. Multiparameter flow cytometry remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood. 2008; 112: 4017-4023.
  • 32
    Rawstron AC, Davies FE, DasGupta R, et al. Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood. 2002; 100: 3095-3100.
  • 33
    Barlogie B, Pineda-Roman M, van RF, et al. Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood. 2008; 112: 3115-3121.
  • 34
    Zangari M, van RF, Anaissie E, et al. Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy. Br J Haematol. 2008; 141: 433-444.
  • 35
    Wang M, Giralt S, Delasalle K, Handy B, Alexanian R. Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma. Hematology. 2007; 12: 235-239.
  • 36
    Corso A, Barbarano L, Mangiacavalli S, et al. Bortezomib with high-dose dexamethasone as first line therapy in patients with multiple myeloma candidates to high-dose therapy [abstract]. Blood (ASH Annual Meeting Abstracts). 2007; 110. Abstract 3595.
  • 37
    Harousseau J-L, Attal M, Leleu X, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica. 2006; 91: 1498-1505.
  • 38
    Harousseau JL, Mathiot C, Attal M, et al. Bortezomib/dexamethasone versus VAD as induction prior to autologous stem cell transplantation (ASCT) in previously untreated multiple myeloma (MM): updated data from IFM 2005/01 trial [abstract]. J Clin Oncol. 2008; 26. Abstract 8505.
  • 39
    Jagannath S, Durie BGM, Wolf JL, et al. Long-term follow-up of patients treated with bortezomib alone and in combination with dexamethasone as frontline therapy for multiple myeloma [abstract]. Blood (ASH Annual Meeting Abstracts). 2006; 108. Abstract 796.
  • 40
    Richardson P, Lonial S, Jakubowiak A, et al. Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma: encouraging efficacy in high risk groups with updated results of a phase I/II study [abstract]. Blood (ASH Annual Meeting Abstracts). 2008; 112. Abstract 92.
  • 41
    Wang M, Delasalle K, Giralt S, Alexanian R. Rapid control of previously untreated multiple myeloma with bortezomib-lenalidomide-dexamethasone (BLD) [abstract]. Blood (ASH Annual Meeting Abstracts). 2007; 110. Abstract 3611.
  • 42
    Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006; 24: 3113-3120.
  • 43
    Richardson PG, Sonneveld P, Schuster MW, et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol. 2009; 144: 895-903.
  • 44
    Mileshkin L, Stark R, Day B, Seymour JF, Zeldis JB, Prince HM. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol. 2006; 24: 4507-4514.
  • 45
    Richardson P, Schlossman R, Jagannath S, et al. Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. Mayo Clin Proc. 2004; 79: 875-882.
  • 46
    Plasmati R, Pastorelli F, Cavo M, et al. Neuropathy in multiple myeloma treated with thalidomide: a prospective study. Neurology. 2007; 69: 573-581.
  • 47
    Zangari M, Elice F, Fink L, Tricot G. Thrombosis in multiple myeloma. Expert Rev Anticancer Ther. 2007; 7: 307-315.
  • 48
    Lonial S, Richardson PG, San MJ, et al. Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma. Br J Haematol. 2008; 143: 222-229.